Research programme: arthritis therapeutics - Oscotec
Latest Information Update: 19 Feb 2016
At a glance
- Originator Oscotec
- Mechanism of Action ADAM protein inhibitors; TYRO3 receptor protein tyrosine kinase antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Arthritis
Most Recent Events
- 19 Feb 2016 Preclinical trials in Arthritis in South Korea (PO)